K. Lafleur

Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4).

A. Caflisch, Danzhi Huang, C. Nevado, 2009, Journal of medicinal chemistry.

Discovery of a novel chemotype of tyrosine kinase inhibitors by fragment-based docking and molecular dynamics.

A. Caflisch, Jing-Jun Dong, Hongtao Zhao, 2012, ACS medicinal chemistry letters.

Iriomoteolides: novel chemical tools to study actin dynamics

A. Caflisch, A. Unzue, C. Nevado, 2018, Chemical science.

Pyrrolo[3,2-b]quinoxaline derivatives as types I1/2 and II Eph tyrosine kinase inhibitors: structure-based design, synthesis, and in vivo validation.

A. Caflisch, Jing-Jun Dong, Hongtao Zhao, 2014, Journal of medicinal chemistry.

Three stories on Eph kinase inhibitors: From in silico discovery to in vivo validation.

S. Zahler, A. Caflisch, P. Kolb, 2016, European journal of medicinal chemistry.

Kinase selectivity potential for inhibitors targeting the ATP binding site: a network analysis

Ting Zhou, Amedeo Caflisch, Danzhi Huang, 2010, Bioinform..

Optimization of Inhibitors of the Tyrosine Kinase Ephb4. 2. Cellular Potency Improvement and Binding Mode Validation by X‑ray Crystallography ■ Lead Optimization Strategy

A. Caflisch, Danzhi Huang, Jing-Jun Dong, 2022 .

Complementing ultrafast shape recognition with an optical isomerism descriptor.

Amedeo Caflisch, Karine Lafleur, A. Caflisch, 2010, Journal of molecular graphics & modelling.

Optimization of inhibitors of the tyrosine kinase EphB4. 2. Cellular potency improvement and binding mode validation by X-ray crystallography.

Danzhi Huang, K. Lafleur, Jing Dong, 2013, Journal of medicinal chemistry.